H.P. Acthar Gel ( DrugBank: - )

---

5 diseases

ID	Disease name (Link within this page)	Number of trials
46	Malignant rheumatoid arthritis	2
49	Systemic lupus erythematosus	1
50	Dermatomyositis	1
84	Sarcoidosis	1
222	Primary nephrotic syndrome	2

46. Malignant rheumatoid arthritis

---

Clinical trials : 4,356 /  Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03082573 (ClinicalTrials.gov)	March 3, 2017	13/3/2017	Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel	Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Were Treated With H.P. Acthar Gel After an Incomplete Response to Combinations of DMARDs and Biologic DMRADs	Rheumatoid Arthritis	Drug: H.P. Acthar gel	Iraj Sabahi Research Inc.	Mallinckrodt	Recruiting	21 Years	N/A	All	30	Phase 4	United States
2	NCT02434757 (ClinicalTrials.gov)	February 2014	30/4/2015	Addition of H.P. Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis	Addition of H. P Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis Inadequately Controlled With Biologic Disease-Modifying Antirheumatic Drugs	Rheumatoid Arthritis	Drug: H.P. Acthar Gel	Ronald J. Rapoport, MD	Questcor Pharmaceuticals, Inc.	Recruiting	18 Years	N/A	Both	10	N/A	United States

49. Systemic lupus erythematosus

---

Clinical trials : 993 /  Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01769937 (ClinicalTrials.gov)	October 2012	15/1/2013	Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus	A Single-site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection)an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)	Lupus Erythematosus Systemic Exacerbation	Drug: H.P. Acthar Gel	Fiechtner, Justus J., M.D., P.C.	NULL	Completed	18 Years	75 Years	Both	10	Phase 4	United States

50. Dermatomyositis

---

Clinical trials : 194 /  Drugs : 244 - (DrugBank : 89) / Drug target genes : 50 - Drug target pathways : 151

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02245841 (ClinicalTrials.gov)	June 15, 2015	11/9/2014	Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis	Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis	Dermatomyositis;Juvenile Dermatomyositis	Drug: H.P. Acthar Gel	The Cleveland Clinic	Mallinckrodt	Completed	18 Years	N/A	All	15	Phase 4	United States

84. Sarcoidosis

---

Clinical trials : 149 /  Drugs : 202 - (DrugBank : 78) / Drug target genes : 66 - Drug target pathways : 169

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02298491 (ClinicalTrials.gov)	May 2016	14/11/2014	CNS Sarcoidosis and Acthar Gel	Clinical Biomarkers of Disease Activity and Treatment Responses in Patients With CNS Sarcoidosis Treated With H.P. Acthar Gel	CNS Sarcoidosis	Drug: H.P. Acthar Gel	University of Maryland, Baltimore	Mallinckrodt	Completed	N/A	N/A	All	4	Phase 4	United States

222. Primary nephrotic syndrome

---

Clinical trials : 310 /  Drugs : 295 - (DrugBank : 117) / Drug target genes : 63 - Drug target pathways : 194

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01386554 (ClinicalTrials.gov)	August 2011	29/6/2011	Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients	A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)	Proteinuria;Idiopathic Membranous Nephropathy	Drug: Repository Corticotropin Injection;Drug: Placebo	Mallinckrodt	NULL	Completed	18 Years	N/A	All	60	Phase 4	United States;Canada;Chile;Mexico;Turkey
2	NCT01155141 (ClinicalTrials.gov)	September 2009	29/6/2010	Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH	Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH	Kidney Diseases	Drug: H.P. Acthar Gel	Stanford University	Mallinckrodt	Completed	16 Years	65 Years	All	15	Phase 4	United States

Back to top